Cytochrome P-450 Polymorphisms and Clinical Outcome in Patients with Non-Small Cell Lung Cancer
| Autor: | Ahmet Oguz Ada, Mumtaz Iscan |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
medicine.medical_specialty CYP2D6 response to chemotherapy medicine.medical_treatment CYP1B1 lcsh:RS1-441 Pharmaceutical Science Review Drug resistance survival lcsh:Pharmacy and materia medica CYP Internal medicine medicine Lung cancer Chemotherapy biology CYP3A4 business.industry Cytochrome P450 respiratory system CYP2E1 medicine.disease lung cancer biology.protein Molecular Medicine polymorphisms business |
| Zdroj: | Turkish Journal of Pharmaceutical Sciences Turkish Journal of Pharmaceutical Sciences, Vol 14, Iss 3, Pp 319-323 (2017) |
| ISSN: | 2148-6247 1304-530X |
| DOI: | 10.4274/tjps.28291 |
| Popis: | Lung cancer is an increasing worldwide public health problem. Most patients with lung cancer have non-small cell lung cancer (NSCLC). These patients are mainly treated with standard platinum-based chemotherapy. Poor response and great inter-individual variety in treatment response occurs among these patients. There is accumulating evidence to support the hypothesis that genetic polymorphisms alter the drug response and survival. Cytochrome P450 (CYP) enzymes metabolize antineoplastic drugs and are involved in drug resistance. Polymorphic CYPs have altered enzyme activities and thus they may influence the response to chemotherapy and survival in patients with lung cancer. In the current review, recent findings with respect to the role of mainly CYP1A1, CYP1B1, CYP2D6, CYP2E1 and CYP3A4 gene polymorphisms in response to chemotherapy and survival in patients with NSCLC have been provided, which could be useful for clinicians in the prognosis of these patients who are mainly treated with platinum-based chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|